Literature DB >> 10092672

Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors.

G Wuytens1, K Verschueren, J P de Winter, N Gajendran, L Beek, K Devos, F Bosman, P de Waele, M Andries, A J van den Eijnden-van Raaij, J C Smith, D Huylebroeck.   

Abstract

Activins are members of the transforming growth factor-beta family of growth and differentiation factors. In this paper, we report the results of a structure-function analysis of activin A. The primary targets for directed mutagenesis were charged, individual amino acids located in accessible domains of the protein, concentrating on those that differ from transforming growth factor-beta2, the x-ray crystal structure of which is known. Based on the activities of the recombinant activin mutants in two bioassays, 4 out of 39 mutant proteins (D27K, K102A, K102E, and K102R) produced in a vaccinia virus system were selected for further investigation. After production in insect cells and purification of these four mutants to homogeneity, they were studied in bioassays and in cross-linking experiments involving transfected receptor combinations. Mutant D27K has a 2-fold higher specific bio-activity and binding affinity to an ActRIIA/ALK-4 activin receptor complex than wild type activin, whereas mutant K102E had no detectable biological activity and did not bind to any of the activin receptors. Mutant K102R and wild type activin bound to all the activin receptor combinations tested and were equipotent in bioassays. Our results with the Lys-102 mutants indicate that the positive charge of amino acid 102 is important for biological activity and type II receptor binding of activins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092672     DOI: 10.1074/jbc.274.14.9821

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.

Authors:  Thomas B Thompson; Teresa K Woodruff; Theodore S Jardetzky
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 3.  Antagonism of activin by activin chimeras.

Authors:  Uwe Muenster; Radhika Korupolu; Ratindra Rastogi; Jessica Read; Wolfgang H Fischer
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

4.  Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.

Authors:  G H Goodfellow; J M Dupret; D M Grant
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

5.  BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.

Authors:  T Kirsch; J Nickel; W Sebald
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

6.  Structure of the ternary signaling complex of a TGF-beta superfamily member.

Authors:  George P Allendorph; Wylie W Vale; Senyon Choe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

7.  A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.

Authors:  Dionys Weber; Alexander Kotzsch; Joachim Nickel; Stefan Harth; Axel Seher; Uwe Mueller; Walter Sebald; Thomas D Mueller
Journal:  BMC Struct Biol       Date:  2007-02-12

8.  Lefty blocks a subset of TGFbeta signals by antagonizing EGF-CFC coreceptors.

Authors:  Simon K Cheng; Felix Olale; Ali H Brivanlou; Alexander F Schier
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.